SNS-301

DRUG2 trials

Sponsors

Sensei Biotherapeutics, Inc.

Conditions

Chronic Myelomonocytic Leukemia (CMML)Myelodysplastic SyndromesSquamous Cell Carcinoma of the Head and Neck

Phase 1

Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

TerminatedNCT04034225

Sensei Biotherapeutics, Inc.Squamous Cell Carcinoma of the Head and Neck

Start: 2019-11-11End: 2021-06-28Updated: 2023-03-24

Phase 2

SNS-301 Monotherapy in High Risk MDS and CMML

WithdrawnNCT04217720

Sensei Biotherapeutics, Inc.Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndromes

Start: 2020-04-01End: 2023-01-01Updated: 2021-08-12

Related Papers

Safety and efficacy of SNS-301 plus pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology2023-06-011 citations

Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology2021-05-201 citations

349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

Regular and Young Investigator Award Abstracts2020-11-012 citations

Safety/efficacy of a phase I/II study of SNS-301 added to pembrolizumab in patients with ASPH+ locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology2020-05-20